Woodline Partners LP Cerevel Therapeutics Holdings, Inc. Transaction History

Woodline Partners LP

  • $9.97 Billion
  • Q2 2024

A detailed history of Woodline Partners LP transactions in Cerevel Therapeutics Holdings, Inc. stock. As of the latest transaction made, Woodline Partners LP holds 335,500 shares of CERE stock, worth $0. This represents 0.14% of its overall portfolio holdings.

Number of Shares
335,500
Previous 600,001 44.08%
Holding current value
$0
Previous $25.4 Million 45.91%
% of portfolio
0.14%
Previous 0.24%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024
SELL
$38.96 - $42.75 $10.3 Million - $11.3 Million
-264,501 Reduced 44.08%
335,500 $13.7 Million
Q1 2024

May 15, 2024
BUY
$40.88 - $43.27 $16.1 Million - $17.1 Million
394,192 Added 191.53%
600,001 $25.4 Million
Q4 2023

Feb 14, 2024
SELL
$20.27 - $42.44 $5.49 Million - $11.5 Million
-270,825 Reduced 56.82%
205,809 $8.73 Million
Q3 2023

Nov 14, 2023
SELL
$20.26 - $31.91 $6.45 Million - $10.2 Million
-318,285 Reduced 40.04%
476,634 $10.4 Million
Q2 2023

Aug 14, 2023
BUY
$23.9 - $35.38 $4.39 Million - $6.49 Million
183,553 Added 30.02%
794,919 $25.3 Million
Q1 2023

May 15, 2023
BUY
$22.82 - $35.32 $3.35 Million - $5.19 Million
146,958 Added 31.64%
611,366 $14.9 Million
Q4 2022

Feb 14, 2023
SELL
$25.35 - $31.96 $1.82 Million - $2.3 Million
-71,977 Reduced 13.42%
464,408 $14.6 Million
Q3 2022

Nov 14, 2022
BUY
$25.5 - $41.42 $7.16 Million - $11.6 Million
280,852 Added 109.91%
536,385 $15.2 Million
Q2 2022

Aug 15, 2022
SELL
$20.62 - $37.15 $2.19 Million - $3.95 Million
-106,220 Reduced 29.36%
255,533 $6.76 Million
Q1 2022

May 16, 2022
BUY
$23.5 - $35.38 $2.92 Million - $4.4 Million
124,427 Added 52.43%
361,753 $12.7 Million
Q4 2021

Feb 14, 2022
BUY
$29.21 - $44.64 $1.23 Million - $1.87 Million
41,995 Added 21.5%
237,326 $7.69 Million
Q3 2021

Nov 15, 2021
BUY
$21.26 - $38.85 $1.1 Million - $2.01 Million
51,619 Added 35.92%
195,331 $5.76 Million
Q2 2021

Aug 16, 2021
SELL
$12.56 - $29.69 $3.13 Million - $7.4 Million
-249,198 Reduced 63.42%
143,712 $3.68 Million
Q1 2021

May 17, 2021
BUY
$12.37 - $17.74 $4.86 Million - $6.97 Million
392,910 New
392,910 $5.4 Million

Others Institutions Holding CERE

# of Institutions
242
Shares Held
154M
Call Options Held
2.19M
Put Options Held
3.87M
View Full List

About Cerevel Therapeutics Holdings, Inc.

CERE Quotes by TradingView
  • Ticker CERE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 155,752,000
  • Description
  • Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...
More about CERE
Track This Portfolio

Track Woodline Partners LP Portfolio

Follow Woodline Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Woodline Partners LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email